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Background: Allergic rhinitis is a global health problem that is often treated with homeopathy. The objective of
this review will be to evaluate the effectiveness of homeopathic treatment of allergic rhinitis.
Methods/Design: The authors will conduct a systematic review. We will search Medline, CENTRAL, CINAHL,
EMBASE, AMED, CAM-Quest, Google Scholar and reference lists of identified studies up to December 2013.
The review will include randomized controlled trials that evaluate homeopathic treatment of allergic rhinitis. Studies
with participants of all ages, with acute or chronic comorbidities will be included. Patients with immunodeficiency
will not be included. The diagnosis will be based on the published guidelines of diagnosis and classification.
Studies of all homeopathy modalities (clinical, complex and classical homeopathy, and isopathy) will be included.
We will include trials with both active controls (conventional therapy, standard care) and placebo controls.
The primary outcomes are: an improvement of global symptoms recorded in validated daily or weekly diaries and
any scores from validated visual analogue scales; the total Quality of Life Score (such as the Juniper RQLQ);
individual symptoms scores which include any appropriate measures of nasal obstruction, runny nose, sneezing,
itching, and eye symptoms; and number of days requiring medication. Secondary outcomes selected will include
serum immunoglobin E (IgE) levels, individual ocular symptoms, adverse events, and the use of rescue medication.
Treatment effects will be measured by calculating the mean difference and the standardized mean difference with
95% confidence interval (CI) for continuous data. Risk ratio or, if feasible, odds ratio will be calculated with 95% CI
for dichotomous data. After assessing clinical and statistical heterogeneity, meta-analysis will be performed, if
appropriate. The individual participant will be the unit of analysis. Descriptive information on missing data will be
included about participants missing due to drop out, whether there was intention to treat or per protocol analysis
and missing statistics. A number of subgroups, homeopathic potency, age groups, and types of allergic rhinitis
(seasonal or perennial) will be analyzed. Sensitivity analysis will be performed to explore the impact of risk of bias
on overall treatment effect.
Systematic review registration: PROSPERO CRD42013006741
Keywords: Homeopathy, Homeopathic, Allergic, Allergy, Rhinitis, Hay fever, Pollinosis, Rhinorrhea, HypersensitivityBackground
Description of the condition
Rhinitis is described as inflammation of the nasal mucosa
and includes common symptoms like nasal discharge,
itching, sneezing, nasal blockage, or congestion. There are
three types of rhinitis commonly seen in clinical practice:
allergic, non-allergic, and infective. Mixed forms also
occur [1]. Allergic rhinitis (AR) is an immunoglobin E* Correspondence: kushal@drkbanerjee.com
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unless otherwise stated.(IgE)-mediated immunologic response of the nasal mu-
cosa to airborne allergens such as pollens, dust, or ani-
mal dander. Inhalation of allergens in individuals with
a sensitized immune system produces degranulation of
mast cells with the release of chemical mediators.
These mediators are responsible for the symptoms of
AR. AR is clinically defined by the presence of rhinorrhea,
nasal obstruction, nasal itching, and sneezing which are
reversible spontaneously or with treatment [2]. Rhinitis af-
fects quality of life, performance and attendance at school
[3], and work. It has significant impact on healthcare costs
[4]. Allergies are responsible for an estimated annuall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Health Services in the United Kingdom [5]. Conven-
tional treatment includes oral or topical antihistamines,
intranasal or systemic corticosteroids, and allergen im-
munotherapy. A cohort of 16-year-olds in the United
Kingdom showed 23% to be suffering from hay fever in
1986 [6].
AR is also a global health problem, affecting 500 mil-
lion patients worldwide (10 to 20% of the population)
[7]. It may commonly be caused by house dust mites,
pollen from grass, trees and weeds, and animal dander.
AR can be broadly classified into seasonal and perennial.
AR has been found to significantly impair psychological
wellbeing and perceived to impair cognitive functioning
[8]. The prevalence of AR is also high in developing
nations: rhino-conjunctivitis was 15.3% amongst 11 to
15 year old school-going children in northern Africa [9].
In addition, there is growing evidence to support a link
between allergic rhinitis and asthma [10].
Several trials have evaluated the effectiveness of hom-
eopathy for AR. Results from these trials are mixed and
their quality is poor. One systematic review involving a
single homeopathic remedy (Galphimia glauca) for treat-
ing AR has been published in English [11]. Three out of
four studies included in that review reported significant
results in favor of the intervention, however, it only in-
cluded one homeopathic medicine. Two important draw-
backs of this review are that of the included trials, neither
used validated outcome measures nor intention-to-treat
analyses. Passalacqua et al. [12] conducted a systematic
review on complementary and alternative medicine for
rhinitis and asthma, concluding that the evidence for a
specific effect of homeopathy is weak. Bellavite et al.
[13] conducted a descriptive review of clinical research
on advances in homeopathy and immunology which
included AR. No meta-analysis was performed in this
review. Apart from Ernst [11], no systematic review
evaluating only homeopathic treatment for allergic
rhinitis has been published in English.
Why is it important to do this review?
No systematic review of all homeopathy modalities for
treating AR has been conducted. A problem with evaluat-
ing classical homeopathy is that it involves an extensive
consultation and an individualized treatment regimen.
Treatment regimens are decided based on disease state
and information gathered in the comprehensive homeo-
pathic case-taking by a qualified homeopathic physician.
Hence two patients with the same (conventional) diagno-
sis may receive very different homeopathic treatments.
Classical homeopathy therefore involves more extensive
consultations which themselves might have effects, at least
for subjective outcomes. Hence apparent positive effects
of classical homeopathy might be difficult to disentanglefrom the effects of longer consultations and other ‘context
effects’ [14,15]. Clinical homeopathy, on the other hand, is
delivered in much the same way that conventional drugs
are prescribed. Complex homeopathy is similar to clinical
homeopathy but more than one remedy is prescribed in a
single formulation. Neither clinical nor complex homeop-
athy requires lengthy and comprehensive homeopathic
case-taking [16,17]. In both of these forms the interven-
tion is linked to a disease state and not individualized for
every patient. Clinical homeopathy, isopathy, and complex
homeopathy could also be more cost-effective and there-
fore more feasible in environments with limited resources
such as India.
A systematic review that includes clinical, complex
homeopathy and isopathy is therefore required to assess
the benefits of homeopathy for treating AR.
Methods/Design
Description of the intervention
The review will include trials of clinical, complex, isopathic,
and classical homeopathy. Homeopathic remedies are de-
fined as medicines listed in homeopathic materia medica
(texts containing symptoms of homeopathic remedies) and
prepared according to the homeopathic pharmacopoeia of
the country in which the trial is being conducted.
Objective
Our primary objective is to determine the efficacy and
effectiveness of homeopathic treatment of AR. Our sec-
ondary aim is to compare the effectiveness of different
forms of homeopathy on AR.
Criteria for including studies for this review
Types of studies
Randomized, double-blinded (both patients and doctors
blinded), controlled trials comparing homeopathy (clas-
sical, clinical, isopathic, or complex) with conventional
treatment, other homeopathy, or placebo, for the treat-
ment of seasonal or perennial AR in patients of any
age.
Types of participants
All age groups (newborn to adult) suffering from any
form of AR will be included. These may include partici-
pants with acute or chronic comorbidities but without
immunodeficiency. Participants may also include those
on conventional treatment for other health issues. Symp-
toms of allergic rhinitis include rhinorrhea, nasal obstruc-
tion, nasal itching, and sneezing which are reversible
spontaneously or with treatment [2]. A diagnosis of AR
will include the following symptoms based on the Guideline
Summary of Management of Allergic and Non Allergic
Rhinitis [7]:
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blockage or congestion, and itchy nose and palate. Eye:
bilateral itchy eyes, red eyes (concomitant allergic con-
junctivitis), and swollen eyes.
There is no specific duration of symptoms required for
diagnosis; however, a very short or non-repetitive history
of symptoms generally excludes a diagnosis of AR. The
presence of any one of the nasal symptoms will be es-
sential for a diagnosis of AR except when nasal blockage
is the only symptom. Nasal blockage on its own rarely
indicates allergy [2]. The duration of symptoms will not
be present as a criterion since this has not been defined
for a diagnosis of AR.
Exclusion criteria for systematic review
The exclusion criteria for this review are as follows: con-
ference proceedings and other abstracted articles in which
risk-of-bias assessments cannot usefully be applied; studies
in which a non-randomized method of sequence gener-
ation and/or a single-blinded approach is explicitly used
by the authors; studies using formulations not described
by the authors as ‘homeopathic’; studies with a crossover
trial design; and studies in which homeopathy is combined
with another intervention.
The exclusion criteria for quantitative data extraction
(for meta-analysis are: studies from which no data are pro-
vided or data are otherwise not extractable. The latter cat-
egory includes studies with continuous outcomes from
which standard deviations are not derivable and those that
report non-parametric data only.
Investigations
Investigations are not always required to confirm diagno-
sis. However, a confirmation of allergic rhinitis sometimes
involves a skin prick test and/or specific and serum total
IgE tests [18]. The use of investigations for confirming
diagnosis will not be an inclusion criterion. Trials allowing
the administration of conventional treatment as a rescue
medication will be included.
Types of interventions
We will include trials involving experimental homeopathic
treatments delivered orally, through olfaction, or applied
on the body. Therefore, globules, nasal sprays, ointments,
and other applications prepared with homeopathic medi-
cines will be included in this review. In these trials the
homeopathic preparations may contain a single medicine
or more than one medicine as in complex homeopathy,
the homeopathic interventions may be administered as
one single preparation or more than one preparation, and
the comparators in the included trials will be placebos or
conventional treatment which may include antihistamines,
immunotherapy, and decongestants and so forth.The alleged difference between homeopathy type
(classical, clinical, and complex) is important and might
be inadequately reported. To deal with this we will use
two strategies. First, we will examine individual studies
to verify the classification of homeopathy type (classical,
clinical, complex, or isopathy) using standard defini-
tions [16]. These are:
‘Classical [individualized] homeopathy: When a single
homeopathic remedy was selected based on the total
symptom picture of a patient.
Clinical homeopathy: When one or several single
remedies were administered for standard clinical
situations or conventional diagnoses.
Complex homeopathy: When multiple remedies were
mixed into a standard formula to ‘cover’ a person’s
symptoms and diagnoses.
Isopathy: When serial agitated dilutions were made
from the causative agent in an infectious or
toxicological condition’ (from Linde et al. [16]).
Therefore when classical homeopathy is used, any
homeopathic medicine may be selected based on com-
prehensive case taking. In clinical homeopathy, for ex-
ample, Allium cepa (a common homeopathic remedy
from onions) may be prescribed based on indications
that match the clinical picture of allergic rhinitis. In
complex homeopathy a preparation containing Luffa oper-
culata, Galphimia glauca, Histamine and Sulphur [19]
may be used to treat AR.
A preparation from an allergen such as Betula (birch)
[20] is an example of an isopathic intervention for AR.
In practice, medicines used by clinical homeopaths may
also be prescribed by classical homeopaths should they
be indicated after comprehensive case-taking. By classi-
fying included studies according to type of homeopathy,
this review will inform practitioners for the first time
about homeopathic medicines according to homeopathy
type for AR.
The current authors’ classification, made according to
these published definitions, will override reported clas-
sifications where appropriate. Second, we will conduct a
subgroup analysis to detect any differences between
homeopathy types for any outcome measure. If a particu-
lar type fails to demonstrate a statistically significant bene-
fit over another then the debate over homeopathy types
becomes moot. On the other hand, if we do find a statisti-
cally significant difference in effects then we will have
shown the importance of specifying homeopathy type.
There will be no limit on the maximum dilution of the
homeopathic medicine. Trials with homeopathic ‘mother
Table 1 Search strategy: homeopathy for allergic rhinitis
Step Search procedure
1 Homeopathy/
2 (Homoeopathy or homoeopathic or homeopathic).mp. [mp =
title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary
concept, rare disease supplementary concept, unique identifier]
3 1 or 2
4 Rhinitis, Allergic, Perennial/or Rhinitis, Vasomotor/or Rhinitis/or
Rhinitis, Atrophic/or Rhinitis, Allergic, Seasonal/
5 (nasal congestion or rhinorrhea or rhinorrhea or sneezing or itchy
nose).mp. [mp = title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol
supplementary concept, rare disease supplementary concept,
unique identifier]
6 Exp Rhinitis/
7 (rhiniti* or rhinoconjunctivitis or SAR or PAR).mp. [mp = title,
abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept,
rare disease supplementary concept, unique identifier]
8 (hay fever or hay next fever or pollinosis or pollenosis).mp. [mp =
title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary
concept, rare disease supplementary concept, unique identifier]
9 4 or 5 or 6 or 7 or 8
10 3 and 9
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group analyses (see below).
Primary outcomes
The primary outcomes of this review are as follows: the
improvement of global symptoms recorded in validated
daily or weekly diaries and any scores from validated visual
analogue scales; the total Quality of Life Score (such as the
Juniper RQLQ); individual symptoms scores which include
any appropriate measures of nasal obstruction, runny
nose, sneezing, itching, and eye symptoms; and the num-
ber of days requiring medication. In case of child partici-
pants, AR symptoms rated by parents will be considered
acceptable.
Secondary outcomes
The secondary outcomes of this review are as follows:
IgE levels, individual ocular symptoms, any adverse event,
hospitalization due to an adverse event, and use of con-
ventional medication (frequency and quantity).
Search
Electronic search
The search to locate randomized trials will be based
on the Cochrane Highly Sensitive Search Strategy [21].
Manual search of the results will supplement the elec-
tronic search.
Medline (1946 to December 2013 inclusive) on Ovid,
CENTRAL, The Cochrane Ear Nose and Throat Disorder
Group Trials Register, CINAHL, EMBASE (1974 to
December 2013) on Ovid, Allied and Complementary
Medicine Database (AMED) (1985 to December 2013)
on Ovid, CAM-Quest and Google Scholar.
The search will not have any language filters. The refer-
ence lists of identified studies will be searched for add-
itional trials and trial authors will be contacted if data are
missing from reports of studies. Filters for randomized
controlled trials, human trials, and so forth will not be
applied.
The search strategy that will be used to search Medline
and adapted for the other sources is detailed in Table 1.
Bibliographies of identified studies and reviews will be
hand searched.
Selection of studies
Studies will be eligible for inclusion if they have a random-
ized, blinded and controlled design, validated measures of
outcome, and evaluate homeopathic treatment for AR.
Two review authors (KB and JH) will independently
review titles and abstracts to select potentially eligible
studies. This will be followed by a full text analysis of
the selected studies to assess compliance with the eligibil-
ity criteria. Disagreements will be resolved by discussion
first. A third author (CC) will arbitrate if the disagreementis due to a difference in interpretation. If no clear
categorization can be made of a selected study it will be
categorized as one that is awaiting assessment. Study au-
thors will be contacted for further information wherever
necessary. RTM may be asked to categorize the study. The
selected studies will then be further evaluated for meth-
odological quality (risk of bias).
Data extraction and management
A data extraction form will be designed and the relevant
details will be transferred to the standard data extraction
sheet after the form is reviewed by all authors. This will
cover study type and methods including number and de-
scription of participants; details of type, mode of admin-
istration, dosage, and duration of intervention; and type,
timing, and measurement method of outcomes. The au-
thors, publication year, and journal of publication will
also be recorded. Two review authors (KB and RTM)
will independently extract data from every included trial
to minimize error and reduce potential bias.
Assessment of risk of bias in included studies
Two review authors (KB and JH) will independently as-
sess the risk of bias of each study using the Cochrane
Risk of Bias Tool from the Cochrane Handbook for Sys-
tematic Reviews of Intervention [22]. These consist of
sequence generation, allocation concealment, blinding
of participants and personnel, blinding of outcome
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come reporting, and other sources of bias.
Each of these factors will be described as reported in
the trial. Attributes of ‘low’, ‘high’, or ‘unclear’ risk will be
made for each of them. We will resolve any disagree-
ments about inclusion of a study by discussion and
consensus first. A third reviewer (CC or RTM) will ar-
bitrate if disagreement is due to difference in interpret-
ation. Trial authors will be contacted if clarification is
required.
Measurement of treatment effect
Baseline comparability of treatment groups for known
prognostic variables will be assessed. For continuous
data, individual and pooled statistics as mean difference
and standardized mean difference with 95% CI will be
calculated. In case of dichotomous outcomes, risk ratios
(or, if feasible, odds ratios) will be calculated with 95%
CI. If appropriate, meta-analysis will be performed after
assessment of clinical or statistical heterogeneity. The in-
dividual participant will be the unit of analysis. Descrip-
tive information on missing data will be included about
participants missing due to dropout, whether there was
intention-to-treat or per-protocol analysis, and about
missing statistics.
Assessment of heterogeneity and reporting biases
Heterogeneity will be assessed by comparing trial popu-
lations, settings, and methods. Statistical heterogeneity
will be assessed using the I2 statistic. A value of greater
than 50% will be considered as important heterogeneity.
Both fixed-effect and random-effect models will be ap-
plied to the data. If the fixed effect and random effect
meta-analyses give identical results then it is unlikely
that there is important statistical heterogeneity, and the
fixed-effect result will be presented. If the results vary,
possible causes of heterogeneity will be examined. This
will inform which result should be reported - stable robust
techniques with an underlying assumption of a fixed effect
(which may be incorrect) or less stable, sometimes unpre-
dictable techniques based on an underlying assumption of
random effect (which may be more likely). A sensitivity
analyses will be performed by conducting the meta-
analysis including and excluding studies which were
deemed to affect heterogeneity. Changes, if any, will be
reported in a table. Funnel plots will be constructed, if
possible. This is a scatter plot of the intervention effect
estimates from individual studies against some measure
(usually the standard error of the mean) of each study’s
sample size or precision.
Data synthesis
Review Manager (RevMan) [Computer program], Ver-
sion 5.2. Copenhagen: The Nordic Cochrane Centre,The Cochrane Collaboration, 2012. RevMan 5.2 will be
used for data synthesis and meta-analysis. The primary
analyses are homeopathy (all forms) compared with pla-
cebo, and homeopathy (all forms) compared with con-
ventional treatment. The additional analyses are: (1)
clinical homeopathy compared with placebo; (2) clinical
homeopathy compared with conventional treatment; (3)
complex homeopathy compared with placebo; (4) com-
plex homeopathy compared with conventional treat-
ment; (5) classical homeopathy compared with placebos;
and (6) classical homeopathy compared with conventional
treatment. We shall compare the pooled effect sizes of: #1
and #3 and #5; #2 and #4 and #6.
Subgroup analyses
If sufficient data are available, subgroup analyses will be
conducted to investigate the effect of homeopathic po-
tency (mother tincture; potency <12C; potency >12C);
different age groups (children versus adults) and differ-
ent types of AR (perennial versus seasonal). It is recog-
nized that there will be relatively low power to detect
effects at the subgroup level; hence these analyses will
be undertaken with the aim of hypothesis generation
only.
Sensitivity analyses
A sensitivity analysis will be performed to explore the
impact of risk-of-bias on overall treatment effect. Studies
will be pooled according to low, uncertain or high risk
of bias. The contribution of studies to heterogeneity will
be assessed.
Discussion
This will be the first systematic review of all types of
homeopathy for allergic rhinitis. We have attempted to
design a robust protocol which should result in an ob-
jective and adequate summary of the available evidence
in this area of research. The review is not limited to
studies published in the English language: such limita-
tion might have excluded several studies that met all
other inclusion criteria. The selected databases index a
large number of CAM journals and the search strategy
is expected to identify most of the relevant studies that
exist.
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